A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

BACKGROUND: Interleukin‐17 antagonists have received a first‐line label for moderate‐to‐severe plaque psoriasis. OBJECTIVES: We conducted the first head‐to‐head trial between the two most commonly used first‐line therapies in Germany, fumaric acid esters (FAEs) and methotrexate, and the interleukin‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Reich, K., Augustin, M., Thaçi, D., Pinter, A., Leutz, A., Henneges, C., Schneider, E., Schacht, A., Dossenbach, M., Mrowietz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187169/
https://www.ncbi.nlm.nih.gov/pubmed/31376153
http://dx.doi.org/10.1111/bjd.18384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187169/
https://www.ncbi.nlm.nih.gov/pubmed/31376153
http://dx.doi.org/10.1111/bjd.18384

Ejemplares similares